4-(4-乙酰基-苯氧基)-丁酸 | 65623-82-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-乙酰基-苯氧基)-丁酸
• 中文别名: 4-(4-乙酰苯氧基)-丁酸
• 英文名称: 4-(4-acetylphenoxy)butanoic acid
• 英文别名: 4-(4-Acetylphenyloxy)butyric acid；4-(4-Acetyl-phenoxy)-butyric acid
• CAS: 65623-82-7
• 化学式: C₁₂H₁₄O₄
• mdl: MFCD03658048
• 分子量: 222.241
• InChiKey: FNHIEZKOCYDCOH-UHFFFAOYSA-N

物化性质

• 沸点：
  426.7±25.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090
• 储存条件：
  | 2-8°C |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Acetyl-phenoxy)-butyric acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Acetyl-phenoxy)-butyric acid
CAS number: 65623-82-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H14O4
Molecular weight: 222.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

ACBut 是一种可切割的奥佐菌素连接物，用于将奥佐菌素与药物结合以构建抗体偶联药（ADC）。

反应信息

• 作为反应物：
  描述：

  4-(4-乙酰基-苯氧基)-丁酸 在 1-羟基苯并三唑 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 tert-butyl (Z)-(2-(((1-(4-(4-((2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)ethyl)amino)-4-oxobutoxy)phenyl)ethylidene)amino)oxy)ethyl)carbamate
  参考文献：
  名称：

  [EN] CALICHEAMICIN CONSTRUCTS AND METHODS OF USE
  [FR] CONSTRUCTIONS DE CALICHÉAMICINE D'ACIDE NUCLÉIQUE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本文提供了含有卡利奇阿霉素的抗体药物结合物（ADCs），以及使用这些ADCs治疗增殖性疾病的方法。

  公开号：

  WO2016172273A1
• 作为产物：
  描述：

  Tert-butyl 4-(4-acetylphenoxy)butanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以90%的产率得到4-(4-乙酰基-苯氧基)-丁酸
  参考文献：
  名称：

  白蛋白结合前药通过可逆的亚氨基硼酸酯形成纳米颗粒用于癌症药物输送

  摘要：

  基于白蛋白的纳米药物是用于癌症药物递送的重要纳米平台。药物被物理封装或与白蛋白或基于白蛋白的纳米系统共价缀合。物理包封是有利的，因为不需要对药物分子进行化学修饰，但是许多药物，例如喜树碱（CPT）和姜黄素（CCM），尽管疏水性很强，但不能与白蛋白一起装载或形成纳米制剂。在本文中，我们证明了前药易于通过亚氨基硼酸盐与蛋白质结合并形成用于癌症药物递送的纳米颗粒。用2-乙酰基苯基硼酸（2-APBA）将CPT和CCM官能化以产生前药CPT-SS-APBA和CCM-APBA。前药通过以下方式与牛血清白蛋白（BSA）结合亚氨基硼酸酯的形成和产生的BSA /前药易于自组装成具有高负载效率，改善的胶体稳定性和大大改善的药代动力学的明确的纳米粒子。纳米颗粒在细胞内酸性环境或富含谷胱甘肽（GSH）的胞质溶胶中有效释放药物。在体内，与皮下使用的4 T1或HepG2肿瘤模型中的临床使用的伊立替康或索拉非尼相比，纳

  DOI：

  10.1016/j.jconrel.2020.12.035

文献信息

• CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF
  申请人：Dynavax Technologies Corporation

  公开号：US20190151462A1

  公开（公告）日：2019-05-23

  The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker. The present disclosure also related to methods for preparation of the cleavable conjugates, uses thereof for stimulating an effective immune response, and uses thereof for the treatment of cancer.

  本公开涉及可切割的结合物（例如，基于颗粒或抗体的结合物），其中包含TLR7/8激动剂（例如，1H-咪唑[4,5-c]喹啉衍生物），包括结合连接物、可切割连接物和自消除连接物。本公开还涉及制备可切割结合物的方法，以及将其用于刺激有效的免疫反应和用于癌症治疗的用途。
• [EN] SPLICEOSTATIN ANALOGS<br/>[FR] ANALOGUES DE SPLICÉOSTATINE
  申请人：PFIZER

  公开号：WO2014068443A1

  公开（公告）日：2014-05-08

  The present invention is directed to novel cytotoxic spliceostatin analogs (I) and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

  本发明涉及新型细胞毒性剪接抑制素类似物（I）及其衍生物，涉及其抗体药物结合物，以及使用它们治疗包括癌症在内的医疗状况的方法。
• Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
  申请人：Tekmira Pharmaceuticals Corporation

  公开号：US09345780B2

  公开（公告）日：2016-05-24

  The invention relates to compositions and methods for site-specific delivery of nucleic acids by combining them with targeting ligands and endosomolytic components.

  这项发明涉及将核酸与靶向配体和内体溶解组分结合，用于特定位点递送核酸的组合物和方法。
• Substituted phenylacetic acid compounds and process for preparation
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04237305A1

  公开（公告）日：1980-12-02

  Substituted phenylacetic acid compounds represented by the following general formula and preparation thereof: ##STR1## wherein R.sup.1 is hydrogen or protected carboxy, R.sup.2 is hydrogen, or protected amino, provided that when R.sup.1 is hydrogen, then R.sup.2 is protected amino, and when R.sup.2 is hydrogen, then R.sup.1 is protected carboxy, R.sup.3 is oxo, hydroxyimino or protected hydroxyimino, R.sup.4 is hydrogen or halogen, and m is an integer of 1 to 3.

  代表以下通式并涉及其制备的取代苯乙酸化合物： ##STR1## 其中R1是氢或保护的羧基，R2是氢或保护的氨基，条件是当R1是氢时，则R2是保护的氨基，而当R2是氢时，则R1是保护的羧基，R3是氧代、羟基亚氨基或保护的羟基亚氨基，R4是氢或卤素，且m是1至3的整数。
• Design, Synthesis, Biological Evaluation and Inhibition Mechanism of 3-/4-Alkoxy Phenylethylidenethiosemicarbazides as New, Potent and Safe Tyrosinase Inhibitors
  作者：Senchuan Song、Yuliang Mai、Huahong Shi、Bing Liao、Fei Wang

  DOI：10.1248/cpb.c19-00949

  日期：2020.4.1

  Tyrosinase plays important roles in many different disease related processes, and the development of its inhibitors is particularly important in biotechnology. In this study, thirty-nine 3-/4-alkoxyphenylethylidenethiosemicarbazides were synthesized as novel tyrosinase inhibitors based on structure-based molecular design. Our experimental results demonstrated that thirty-one of them possess remarkable tyrosinase inhibitory activities with IC50 value below 1 µM, and 5a, 6e, 6g and 6t did not display any toxicity to 293T cell line at the concentration of 1000 µmol/L. According to the inhibitory activities, several compounds were selected for detail investigation on the structure–activity relationships (SARs), mechanisms of enzyme inhibition, inhibitory kinetics and cytotoxicity. In particular, the interaction between the selected inhibitors and the active center of tyrosinase was considered and discussed in detail based on their structural characteristics. Taken together, the results presented here demonstrated that the newly designed compounds are promising candidates for the treatment of tyrosinase-related disorders and further development of them may have significant contribution in biomedical science.

  酪氨酸酶在多种与疾病相关的过程中扮演重要角色，其抑制剂的研发在生物技术领域尤为重要。本研究基于结构导向的分子设计，合成了39种新颖的3-/4-烷氧基苯乙烯基二唑半卡巴唑类化合物作为酪氨酸酶抑制剂。我们的实验结果显示，其中31种化合物的酪氨酸酶抑制活性显著，IC50值低于1µM，且5a、6e、6g和6t在1000µmol/L浓度下对293T细胞系无毒性。根据抑制活性，选取了若干化合物详细研究了构效关系、酶抑制机制、抑制动力学及细胞毒性。特别是，基于这些化合物的结构特征，详细考虑并讨论了所选抑制剂与酪氨酸酶活性中心的相互作用。综上所述，本研究结果表明，新设计的化合物是治疗与酪氨酸酶相关疾病的潜在候选药物，其进一步开发可能对生物医学科学产生重大贡献。